RIFAPENTINE, 300mg, break. tab., blister
Valid Article
OC subscriptions: included in supply or field order tools (e.g. UniField)
|
|
SC subscriptions: included in supply or field tools
|
|
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
|
|
RIFAPENTINE
Therapeutic Action
Rifamycin, bactericidal
Indications
Latent Tuberculosis Infection (LTI-TB), in combination with isoniazid
Instructions for use
The 150 mg dispersible tablet is intended for paediatric use.
The 150 mg normal tablet would be reserved to complement adult treatment, if needed, to achieve a daily dose of 750 mg (300x2+150), and as an alternative to the dispersible tablet in case of supply constraints.
For children over 14 years of age and adults, prefer the fixed-dose combination (FDC): ISONIAZID 300mg / RIFAPENTINE, 300mg, tab., blister.
Blister packaging is the packaging of choice for antituberculosis medicines due to the unstable nature of some of them when exposed to higher temperatures and humidity.
The quantity to be ordered is calculated per tablet, not per blister.
Precautions for Use
Do not administer in children under 2 years of age.
Storage
Below 25°C - Protect from sunlight, Protect from humidity
![[DORAHRIP33TB1] ISONIAZID 300mg / RIFAPENTINE, 300mg, break. tab., blister](/web/image/product.template/573328/image_256/%5BDORAHRIP33TB1%5D%20ISONIAZID%20300mg%20-%20RIFAPENTINE%2C%20300mg%2C%20break.%20tab.%2C%20blister?unique=864337a)
![[DORARIFP1TD1] RIFAPENTINE, 150mg, disp. tab., blister](/web/image/product.template/586330/image_256/%5BDORARIFP1TD1%5D%20RIFAPENTINE%2C%20150mg%2C%20disp.%20tab.%2C%20blister?unique=864337a)